

DAFTAR PUSTAKA

1. Albuquerque AFM, Fonteles CSR, do Val DR, Chaves H V., Bezerra MM, Pereira KMA, et al. Effect of pre-emptive analgesia on clinical parameters and tissue levels of TNF- α and IL-1 β in third molar surgery: a triple-blind, randomized, placebo-controlled study. *Int J Oral Maxillofac Surg.* 2017;46(12):1615–25. doi:10.1016/j.ijom.2017.05.007
2. Yilmaz S, Adisen MZ, Misirlioglu M, Yorubulut S. Assessment of Third Molar Impaction Pattern and Associated Clinical Symptoms in a Central Anatolian Turkish Population. *Medical Principles and Practice.* 2016;25(2):169–75.
3. Degirmenci A, Yalcin E. The effect of pregabalin and ibuprofen combination for pain after third molar surgery. *Niger J Clin Pract.* 2019;22(4):503–10.
4. Manuapo H, Sudjud RW, Tavianto D. Perbandingan Preemptive Analgesia Kombinasi Ibuprofen 75 Miligram dan Paracetamol 250 Miligram per Oral dengan Paracetamol 1 Gram per Oral terhadap Lama Analgesik Pascabedah Odontektomi. *Jurnal Anestesi Perioperatif.* 2019;7(3): 2019;7(38):181–7.
5. Gascon N, Almansa C, Merlos M, Miguel Vela J, Encina G, Morte A, et al. Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic. *Expert Opin Investig Drugs.* 2019;28(5):399–409. doi:10.1080/13543784.2019.1612557
6. López-Cedrún J, Videla S, Burgueño M, Juárez I, Aboul-Hosn S, Martín-Granizo R, et al. Co-crystal of Tramadol–Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding,

- Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial. *Drugs in R and D.* 2018;18(2):137–48.
7. Atkinson HC, Currie J, Moodie J, Carson S, Evans S, Worthington JP, et al. Combination paracetamol and ibuprofen for pain relief after oral surgery: A dose ranging study. *Eur J Clin Pharmacol.* 2015;71(5):579–87.
 8. Daniels SE, Playne R, Stanescu I, Zhang J, Gottlieb IJ, Atkinson HC. Efficacy and Safety of an Intravenous Acetaminophen / Ibuprofen Fixed-dose Combination After Bunionectomy : a Randomized , Double-blind ., *Clin Ther.* 2019;41(10):1982-1995.e8. doi: 10.1016/j.clinthera.2019.07.008
 9. Hsing CH, Wang JJ. Clinical implication of perioperative inflammatory cytokine alteration. Vol. 53, *Acta Anaesthesiologica Taiwanica.* Elsevier Taiwan LLC; 2015. p. 23–8.
 10. Takdir Musba A, Tantra H, Yusuf I, Ahmad R. The preoperative single dose dexamethasone effect to pro-and anti-inflammatory cytokine during orthopedic surgery. *Indian Journal of Pain.* 2015;29(2):100.
 11. Morris P, Ali K, Merritt M, Pelletier J, Macedo LG. A systematic review of the role of inflammatory biomarkers in acute, subacute and chronic non-specific low back pain. Vol. 21, *BMC Musculoskeletal Disorders.* BioMed Central Ltd.; 2020.
 12. Nielsen R V., Siegel H, Fomsgaard JS, Andersen JDH, Martusevicius R, Mathiesen O, et al. Preoperative dexamethasone reduces acute but not sustained pain after lumbar disk surgery: A randomized, blinded, placebo-controlled trial. *Pain.* 2015;156(12):2538–44.

13. Lu D. *Atlas of Wisdom Teeth Surgery*. Lu D, editor. *Atlas of Wisdom Teeth Surgery*. Singapore: Springer; 2019.
14. Ali AS, Benton JA, Yates JM. Risk of inferior alveolar nerve injury with coronectomy vs surgical extraction of mandibular third molars—A comparison of two techniques and review of the literature. *J Oral Rehabil*. 2018;45(3):250–7.
15. Lita YA, Hadikrishna I. Klasifikasi impaksi gigi molar ketiga melalui pemeriksaan radiografi sebagai penunjang odontektomi. *Jurnal Radiologi Dentomaksilosial Indonesia*. 2020;4(1):1.
16. Park KL. Which factors are associated with difficult surgical extraction of impacted lower third molars? *J Korean Assoc Oral Maxillofac Surg*. 2016;42(5):251.
17. Demirbas AE, Karakaya M, Bilge S, Canpolat DG, Küttük N, Alkan A. Does Single-Dose Preemptive Intravenous Ibuprofen Reduce Postoperative Pain After Third Molar Surgery? A Prospective, Randomized, Double-Blind Clinical Study. *Journal of Oral and Maxillofacial Surgery*. 2019;77(10):1990–7.
18. Evans SW, McCahon RA. Management of postoperative pain in maxillofacial surgery. *British Journal of Oral and Maxillofacial Surgery*. 2019;57(1):4–11. doi: 10.1016/j.bjoms.2018.11.010
19. Sirintawat N, Sawang K, Chaiyasamut T, Wongsirichat N. Pain measurement in oral and maxillofacial surgery. *J Dent Anesth Pain Med*. 2017;17(4):253.
20. Yam MF, Loh YC, Tan CS, Adam SK, Manan NA, Basir R. General

- pathways of pain sensation and the major neurotransmitters involved in pain regulation. *Int J Mol Sci.* 2018;19(8).
21. Solepure DAB. Physiology of Pain a Review. *Journal of Medical Science And clinical Research.* 2020;08(12):224–33.
 22. Kang S, Tanaka T, Narasaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. *Immunity.* 2019;50(4):1007–23.doi: 10.1016/j.immuni.2019.03.026
 23. Luggya TS, Roche T, Ssemogerere L, Kintu A, Kasumba JM, Kwizera A, et al. Effect of low-dose ketamine on post-operative serum IL-6 production among elective surgical patients: A randomized clinical trial. *Afr Health Sci.* 2017;17(2):500–7.
 24. Taufiqurrachman T, Mulyo K. Perbandingan Pengaruh Pemberian Analgetik Etoricoxib Dengan Natrium Diclofenak Terhadap Rasa Nyeri Pasca Odontektomi (Impaksi Kelas 1, Molar 3 Rahang Bawah). *Jurnal Kedokteran Diponegoro.* 2016;5(3):222–34.
 25. Viswanath A, Oreadi D, Finkelman M, Klein G, Papageorge M. Does Pre-Emptive Administration of Intravenous Ibuprofen (Caldolor) or Intravenous Acetaminophen (Ofirmev) Reduce Postoperative Pain and Subsequent Narcotic Consumption After Third Molar Surgery? *Journal of Oral and Maxillofacial Surgery* 2019;77(2):262–70.doi : 10.1016/j.joms.2018.09.010
 26. Forouzanfar MM, Mohammadi K, Hashemi B, Safari S. Comparison of intravenous ibuprofen with intravenous ketorolac in renal colic pain management; A clinical trial. *Anesth Pain Med.* 2019;9(1):1–7.

27. Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques a review. *JAMA Surg.* 2017;152(7):691–7.
28. Hinther A, Nakoneshny SC, Chandarana SP, Matthews TW, Hart R, Schrag C, et al. Efficacy of multimodal analgesia for postoperative pain management in head and neck cancer patients. *Cancers (Basel).* 2021;13(6):1–11.
29. Beverly A, Kaye AD, Ljungqvist O, Urman RD. Essential Elements of Multimodal Analgesia in Enhanced Recovery After Surgery (ERAS) Guidelines. *Anesthesiol Clin.* 2017;35(2):e115–43.
30. Derry S, Wiffen PJ, Moore RA. Single dose oral ibuprofen plus caffeine for acute postoperative pain in adults. *Cochrane Database of Systematic Reviews.* 2015(2).
31. Park A, Anderson D, Battaglino RA, Morse LR. Ibuprofen use is associated with reduced C-reactive protein and interleukin-6 levels in chronic spinal cord injury. *J Spinal Cord Med.* 2022;45(1):117–25. doi: 10.1080/10790268.2020.1773029
32. Chmiel JF, Konstan MW, Accurso FJ, Lymp J, Mayer-Hamblett N, VanDevanter DR, et al. Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. *Journal of Cystic Fibrosis.* 2015;14(6):720–6. doi: 10.1016/j.jcf.2015.03.007
33. Pinar HU, Karaca Ö, Karakoç F, Doğan R. Effects of Addition of Preoperative Intravenous Ibuprofen to Pregabalin on Postoperative Pain in Posterior Lumbar Interbody Fusion Surgery. *Pain Res Manag.* 2017;2017.

34. Koh W, Nguyen KP, Jahr JS. Intravenous non-opioid analgesia for peri-and postoperative pain management: A scientific review of intravenous acetaminophen and ibuprofen. *Korean J Anesthesiol*. 2015;68(1):3–12.
35. Erdi AM, Arabzadeh A, Isazadehfari K. Comparing the Efficacy and Side Effects of Intravenous Ibuprofen and Acetaminophen in Pain Control Following Laparoscopic Cholecystectomy. 2022;11(1):117–24.
36. Akbas S, Ozkan AS, Durak MA, Yologlu S. Pain and Morphine Consumption in Lumbar Disc Surgery: Prospective .,. Neurochirurgie. 2021;1–7. doi :10.1016/j.neuchi.2021.04.019
37. Andribert L, Pontoh P. The Use of Combination Paracetamol and Ibuprofen in Postoperative Pain after Total Knee Arthroplasty, a Randomized Controlled Trial. *Pain Phycisian Journal*. 2021;24:1199–204.
38. Lisboa FA, Bradley MJ, Hueman MT, Schobel SA, Gaucher BJ, Styrmisdottir EL, et al. Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity wounds. *Surgery* (United States). 2017;161(4):1164–73. doi: 10.1016/j.surg.2016.10.011
39. Chmiel JF, Konstan MW, Accurso FJ, Lymp J, Mayer-Hamblett N, VanDevanter DR, et al. Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. *Journal of Cystic Fibrosis*. 2015 Nov 1;14(6):720–6.
40. Afif Y, Gaus S, Ambo A. Comparison of Multimodal Analgesia for Pain Control and Measuring Inflammation Levels Using Paracetamol with

- Various Dosage of Ibuprofene in Caesarian Surgical Patients. Jurnal Kesehatan. 2022;15(1):71–8.
41. Khan AN, Jacobsen HE, Khan J, Filippi CG, Levine M, Lehman RA, et al. Inflammatory biomarkers of low back pain and disc degeneration: a review. Vol. 1410, Annals of the New York Academy of Sciences. Blackwell Publishing Inc.; 2017. p. 68–84.
 42. Supomo. Correlation of Interleukin-6 Serum Level and Surgical Site Infection in Post Major Surgery Patient. Bali Medical Journal. 2019;8(1):18–20.
 43. Reikeras O, Borgen P, Reseland JE, Lyngstadaas SP. Changes in serum cytokines in response to musculoskeletal surgical trauma. BMC Res Notes. 2014;7(1):1–5.

LAMPIRAN

Lampiran 1. Surat izin penelitian di RSPTN Unhas

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN



FAKULTAS KEDOKTERAN GIGI

Jl. Perintis Kemerdekaan Km. 10, Makassar 90245
Telepon (0411) 586012, 584641 Faximile. (0411) 584641
Website : <http://dent.unhas.ac.id>, Email: fdhu@unhas.ac.id

No : 2004/UN4.13.1/PT.01.04/2022
Perihal : **Izin Penelitian**

28 Juni 2022

Kepada Yth.
Direktur Rumah Sakit Pendidikan Tinggi Negeri (RSPTN)
Universitas Hasanuddin
Makassar

Dengan hormat kami sampaikan bahwa mahasiswa dari Program Pendidikan Dokter Gigi Spesialis (PPDGS) Bedah Mulut dan Maksillofasial Fakultas Kedokteran Gigi Universitas Hasanuddin bermaksud untuk melakukan penelitian.

Sehubungan dengan hal tersebut, kiranya dapat diberikan **izin penelitian** kepada peneliti di bawah ini:

Nama, NIM : Nilawati, drg. (J045192004)
Waktu Penelitian : Juli s.d. Desember 2022
Tempat Penelitian : Rumah Sakit Pendidikan Tinggi Negeri (RSPTN) Unhas
Judul Penelitian : “Efektivitas kombinasi ibuprofen dan paracetamol intravena terhadap kualitas analgesia pasca operasi odontektoni molar tiga”.

Demikian permohonan kami atas perhatian dan kerjasamanya diucapkan terima kasih.



a.n. Dekan
Wakil Dekan Bidang Akademik, Riset dan
Inovasi
Prof. Dr. Edy Machmud, drg., Sp.Pros (K)
NIP 19631104 199401 1 001

Tembusan Yth:
1. Dekan FKG Unhas;
2. Kepala Bagian Tata Usaha FKG Unhas;

Lampiran 2 Surat izin penelitian di RSGMP Unhas

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN



FAKULTAS KEDOKTERAN GIGI

Jl. Perintis Kemerdekaan Km. 10, Makassar 90245
Telepon (0411) 586012, 584641 Faximile. (0411) 584641
Website : <http://dent.unhas.ac.id>, Email: fdhu@unhas.ac.id

No : 2222/UN4.13.1/PT.01.04/2022
Perihal : **Izin Penelitian**

13 Juli 2022

Kepada Yth.
Direktur Rumah Sakit Gigi dan Mulut Pendidikan (RSGMP)
Universitas Hasanuddin
Makassar

Dengan hormat kami sampaikan bahwa mahasiswa dari Program Pendidikan Dokter Gigi Spesialis (PPDGS) Bedah Mulut dan Maksillofasial Fakultas Kedokteran Gigi Universitas Hasanuddin bermaksud untuk melakukan penelitian.

Sehubungan dengan hal tersebut, kiranya dapat diberikan **izin penelitian** kepada peneliti di bawah ini:

Nama, NIM : **Nilawati, drg. (J045192004)**

Waktu Penelitian : Juli s.d. Desember 2022

Tempat Penelitian : Rumah Sakit Gigi dan Mulut Pendidikan (RSGMP) Unhas

Judul Penelitian : “Efektivitas kombinasi ibuprofen dan paracetamol intravena terhadap kualitas analgesia pasca operasi odontektomi molar tiga”.

Demikian permohonan kami atas perhatian dan kerjasamanya diucapkan terima kasih.

a.n. Dekan
Wakil Dekan Bidang Akademik, Riset dan Inovasi

Prof. Dr. Edy Machmud, drg., Sp.Pros (K)
NIP 19631104 199401 1 001

Tembusan Yth:
1. Dekan FKG Unhas;
2. Kepala Bagian Tata Usaha FKG Unhas;



Lampiran 3 Rekomendasi Persetujuan Etik



REKOMENDASI PERSETUJUAN ETIK

Nomor: 0102/PL.09/KEPK FKG-RSGM UNHAS/2022

Tanggal: 27 Juli 2022

Dengan ini menyatakan bahwa protokol dan dokumen yang berhubungan dengan protokol berikut ini telah mendapatkan persetujuan etik:

No. Protokol	UH 17120682	No Protokol Sponsor	
Peneliti Utama	drg. Nilawati	Sponsor	Pribadi
Judul Peneliti	Efektivitas Kombinasi Ibuprofen dan Paracetamol Intravena terhadap Kualitas Analgesia Pasca Operasi Odontektomi Molar Tiga		
No. Versi Protokol	1	Tanggal Versi	07 Juli 2022
No. Versi Protokol		Tanggal Versi	
Tempat Penelitian	RSGMP UNHAS, RSPTN UNHAS		
Dokumen Lain			
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard	Masa Berlaku 27 Juli 2022- 27 Juli 2023	Frekuensi Review Lanjutan
Ketua Komisi Etik Penelitian	Nama: Dr. drg. Marhamah, M.Kes.	Tanda Tangan	Tanggal
Sekretaris Komisi Etik Penelitian	Nama: drg. Muhammad Ikbal, Sp.Pros	Tanda Tangan	Tanggal

Kewajiban peneliti utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum diimplementasikan
- Menyerahkan laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan lapor SUSAR dalam 72 jam setelah peneliti ulama menerima laporan.
- Menyerahkan laporan kemajuan (*progress report*) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah.
- Menyerahkan laporan akhir setelah penelitian berakhir.
- Melaporkan penyimpangan dari protokol yang disetujui (*protocol deviation/violation*)
- Mematuhi semua aturan yang berlaku.

Lampiran 4. Lembar Informed Consent

N. 1 (1)

SURAT PERNYATAAN KESEDIAAN MENJADI SUBYEK PENELITIAN

Dengan ini saya,

Nama : ADOUL RINDJAL RAZAK

Umur : 20 TAHUN

Jenis Kelamin Laki-laki Perempuan

Setelah mendapat penjelasan secukupnya mengenai manfaat dan resiko penelitian dengan judul :


"Efektivitas Kombinasi Ibuprofen dan Paracetamol Intravena Terhadap Kualitas Analgesia Pasca Operasi Odontektomi Molar Tiga"

Dengan ini menyatakan bahwa saya bersedia dengan suka rela berpartisipasi menjadi subjek penelitian tersebut.

Demikian pernyataan ini saya buat dengan sebenarnya dengan penuh kesadaran dan tanpa paksaan.

Makassar 06 / 07 / 2022

Peneliti, Yang Berpartisipasi,


(drg. Nilawati)


(.....ADOUL RINDJAL RAZAK.....)

Lampiran 5. Lembar pemeriksaan VAS

(3)

FORM PEMERIKSAAN SKALA NYERI

Nama / JK	: Azizah Azzahra Sudirman	No. Urut Sampel	: BSC 31 / T / AC
TTL/ Usia	: 22 tahun	Kelompok Sampel	: Paracetamol
Alamat	: Wajo	DPJP	: drg. Hadiira, M.KB. SpMM(K)
No. HP	: 085 298 573 919	Diagnosa	: Impaksi Gigi 18-28,92

WAKTU	SKOR	KATEGORI
PRE OPERASI : _____	: 0	Tidak ada nyeri
2 JAM POST OP : _____	: 80	Nyeri Berat
8 JAM POST OP : _____	: 60	Nyeri Sedang
16 JAM POST OP : _____	: 40	Nyeri Ringan
24 JAM POST OP : _____	: 30	Nyeri Ringan
POD 3 HARI : _____	: 10	Nyeri Ringan
POD 5 HARI : _____	: 5	Nyeri ringan
POD 7 HARI : _____	: 0	Tidak ada nyeri

KELUHAN TAMBAHAN POST OP 24 JAM

- MUAL : tidak ada
- MUNTAH : tidak ada
- REAKSI ALERGI : tidak ada

SKOR VAS

- TIDAK NYERI : 0 - 4 mm
- NYERI RINGAN : 5 - 44 mm
- NYERI SEDANG : 45 - 74 mm
- NYERI BERAT : 75 - 100 mm

Lampiran 6. Data hasil pemeriksaan nilai IL-6

QuantitativeCurveFit1																											
Parameters																											
Fit to		Assay: Calibrator																									
Fit type		Four Parameter Logistic																									
Concentration transform		Linear																									
Measurement transform		Linear																									
Markers		Mean																									
Formula		$y = d + (a - d)/(1 + (x / c)^b)$																									
Parameter a		0,2138																									
Parameter b		1,1997																									
Parameter c		186,8780																									
Parameter d		4,1221																									
Coefficient of determination R ²		0,9993																									
Plate	Well	Sample	Conc.	Original [A]	Fitted [A]	Abs Residual																					
Plate 1	A01	Cal_0001	320,0000	2,7749	2,7774	-0,0025																					
		Cal_0001	320,0000	2,7749	2,7774	-0,0025																					
		Cal_0002	160,0000	1,9972	1,9864	0,0108																					
Plate 1	B01	Cal_0002	160,0000	1,9972	1,9864	0,0108																					
		Cal_0003	80,0000	1,2296	1,2512	-0,0216																					
		Cal_0004	40,0000	0,7678	0,7451	0,0227																					
Plate 1	C01	Cal_0004	40,0000	0,7678	0,7451	0,0227																					
		Cal_0005	20,0000	0,4549	0,4643	-0,0094																					
		Cal_0005	20,0000	0,4549	0,4643	-0,0094																					
Plate 1: Plate 1																											
Abs		1	2	3	4	5	6	7	8	9	10	11	12														
A		2,7749	0,8666	0,6062	0,7374	0,6957	0,7146	0,7452	0,8438	0,8585	0,8023	0,9959	0,4492														
B		1,9972	0,7869	0,6450	0,6937	0,7130	0,7072	0,6917	1,8722	0,7807	0,8213	0,9992	1,5608														
C		1,2296	0,8438	0,7197	0,7312	0,7542	0,6163	0,7971	2,0782	0,6828	0,7859	0,7702	0,8801														
D		0,7678	0,7598	0,7805	0,6894	0,6506	0,6141	0,7379	0,7949	0,6189	2,2905	0,7624	0,9724														
E		0,4549	0,7409	0,7528	0,6985	1,1483	0,6012	0,7154	0,7928	0,6738	1,8668	0,9147	0,8863														
F		1,2746	0,6897	0,8384	1,2916	0,7049	0,6369	0,7460	0,8258	0,7930	0,8689	0,9226															
G		0,9280	1,0526	0,7253	0,7871	0,6903	0,6978	0,6849	0,7094	0,8078	0,8749	1,2880	0,9261														
H																											
Fitted conc		1	2	3	4	5	6	7	8	9	10	11	12														
A		48,9668	30,0470	39,4439	36,4339	37,7950	40,0099	47,2614	48,3596	44,1861	58,8828	NaN															
B		43,0538	32,8057	36,2902	37,6795	37,2615	36,1465	144,9263	42,5993	45,5896	59,1419	109,3793															
C		47,2614	38,1631	38,9947	40,6643	30,7639	43,8033	173,0988	35,5078	42,9805	41,8311	49,9822															
D		41,0722	42,5846	35,9814	33,2050	30,6077	39,4802	43,6415	30,9486	207,5073	41,2617	57,0471															
E		39,6978	40,5624	36,6352	71,2074	29,6924	37,8527	43,4871	34,8629	144,2443	52,6048	50,4500															
F		82,0587	36,0029	46,8592	53,5694	37,0958	32,2287	40,0680	45,9231	43,5018	49,1395	53,2078															
G		53,6209	63,3797	38,5678	43,0685	36,0460	36,5689	35,6584	37,4200	44,5916	49,5906	83,2485	53,4755														
H																											
Sample		1	2	3	4	5	6	7	8	9	10	11	12														
A		Cal_0001	Un_0002	1	Un_0009	1	Un_0016	1	Un_0023	1	Un_0030	1	Un_0037	1	Un_0044	1	Un_0051	1	Un_0058	1	Un_0065	1	Un_0072	1	1		
B		Cal_0002	Un_0003	1	Un_0010	1	Un_0017	1	Un_0024	1	Un_0031	1	Un_0038	1	Un_0045	1	Un_0052	1	Un_0059	1	Un_0066	1	Un_0073	1	1		
C		Cal_0003	Un_0004	1	Un_0011	1	Un_0018	1	Un_0025	1	Un_0032	1	Un_0039	1	Un_0046	1	Un_0053	1	Un_0060	1	Un_0067	1	Un_0074	1	1		
D		Cal_0004	Un_0005	1	Un_0012	1	Un_0019	1	Un_0026	1	Un_0033	1	Un_0040	1	Un_0047	1	Un_0054	1	Un_0061	1	Un_0068	1	Un_0075	1	1		
E		Cal_0005	Un_0006	1	Un_0013	1	Un_0020	1	Un_0027	1	Un_0034	1	Un_0041	1	Un_0048	1	Un_0055	1	Un_0062	1	Un_0069	1	Un_0076	1	1		
F		Un_0007	1	Un_0014	1	Un_0021	1	Un_0028	1	Un_0035	1	Un_0042	1	Un_0049	1	Un_0056	1	Un_0063	1	Un_0070	1	Un_0077	1	1			
G		Un_0001	1	Un_0008	1	Un_0015	1	Un_0022	1	Un_0029	1	Un_0036	1	Un_0043	1	Un_0050	1	Un_0057	1	Un_0064	1	Un_0071	1	Un_0078	1	1	
H																											
Dilution		1	2	3	4	5	6	7	8	9	10	11	12														
A		01:01	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1														
B		1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1														
C		1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1														
D		1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1														
E		1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1														
F		1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1														
G		1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1														
H																											
Result		1	2	3	4	5	6	7	8	9	10	11	12														
A		48,9668	30,0470	39,4439	39,4339	37,7950	40,0099	47,2614	48,3596	44,1861	58,8828	84,3217															
B		43,0538	30,8057	36,2902	37,6795	37,2615	36,1465	144,9263	42,5993	45,5896	59,1419	49,3793															
C		47,2614	38,1631	38,9947	40,6643	30,7639	43,8033	173,0988	35,5078	42,9805	41,8311	49,9822															
D		41,0722	42,5846	35,9814	33,2050	30,6077	39,4802	43,6415	30,9486	207,5073	41,2617	57,0471															
E		39,6978	40,5624	36,6352	71,2074	29,6924	37,8527	43,4871	34,8629	144,2443	52,6048	50,4500															
F		82,0587	36,0029	46,8592	53,5694	37,0958	32,2287	40,0680	34,7634	43,5018	49,1395	53,2078															
G		53,6209	63,3797	38,5678	43,0685	39,0460	36,5689	35,6584	37,4200	44,5916	49,5906	83,2485	53,4755														
H																											

Lampiran 7. Rekapitulasi Data Penelitian

No	Nama Pasien	JK	(tahun)	BB (Kg)	(Cm)	(KgM2)	Diagnosa	Gigi	BF+PC	PCT	Pre OP	2 jam	8 jam	16 jam	24 jam	POD 3	POD 5	POD 7	Pre Op	24 jam post op	
1	Abdul Ridjal Razak	L	20	64	167	22.9	18,28 B SA, 38,48 II A Hori	4	0	1	0	17	10	8	4	8	0	0	53.6209	43.0538	
2	Sesty Raharja	P	30	65	159	25.7	18 B SA, 38 II A Verti, 48 II A Verti	3	0	1	0	72	18	4	4	1	1	1	47.2614	39.6378	
3	Santalia Rikkas	P	41	65	169	22.8	18,28 B SA, 38 II B Hori, 48 II A Verti	4	0	1	0	9	21	4	6	4	4	1	82.0587	63.3797	
4	Antonius	L	22	57	171	19.5	18,28 B SA, 38,48 II A Hori	4	0	1	0	15	6	10	20	18	35	0	30.0470	30.8057	
5	Abd. Hidayat	L	24	70	171	23.9	18,28 B SA, 38,48 II A Hori	4	1	0	0	1	0	0	0	5	6	2	38.1631	42.5846	
6	M. Hidayat Hairuddin	L	18	75	160	27.5	18 A SA, 28 B SA, 38 II B Mesio, 48 II B Verti	4	1	0	0	26	5	3	3	2	0	0	40.5624	36.0029	
7	Nurul Rahmadiani	P	23	51	152	22.1	18,28 B SA, 38,48 II B Mesio	4	1	0	0	18	6	7	5	5	0	0	38.5678	39.4439	
8	Febri Mulawardi	L	18	52	160	20.3	18,28 C SA, 38 II B Mesio	3	1	0	0	4	5	5	5	0	0	0	36.2902	38.9347	
9	Saputra Ibnu Sahlaz	L	19	58	165	21.3	18 C SA, 38 II B mesio, 48 II B vertikal	3	1	0	0	7	6	7	4	2	1	0	36.9814	36.6352	
10	Baso Safaruddin	L	22	52	164	19.3	18,28 C SA, 38,48 II B Hori	4	1	0	0	0	0	0	0	0	0	0	46.8592	43.0685	
11	Nur haliza	P	18	44	150	19.6	18 B SA, 28 C SA, 48 II C mesio	3	1	0	0	70	65	27	43	43	25	0	39.4339	37.6795	
12	Ariyen Duri	P	23	53	155	22.1	18,28 B SA, 38 II A Verti	3	1	0	0	50	50	50	20	10	10	0	40.6643	33.2050	
13	Asyhari Lukman	L	26	49	166	17.8	18,28 A SA, 38,48 II A Hori	4	1	0	0	0	0	0	0	0	0	0	71.2074	53.5694	
14	Andi Kemala Andini	P	25	74	160	29.3	18,28 B SA, 38,48 II B Hori	4	1	0	0	0	0	0	0	0	0	0	39.0460	37.7950	
15	Galuh Lutfiah (RSP)	P	19	60	155	25	18,28 B SA, 38,48 II B Mesio	4	0	1	0	31	18	0	0	0	0	0	37.2615	30.7639	
16	Arfandi	L	23	55	170	18	18,28 B NSA, 48 II B Verti	3	1	0	0	62	53	52	35	22	10	8	30.6077	29.6324	
17	Yustika	P	23	57	153	24.3	18,28 B SA, 38 II A Verti	3	1	0	0	0	0	0	0	0	0	0	37.0958	36.5849	
18	Angga Boimau	L	19	60	170	23.2	18,28 C SA, 38,48 II A Hori	4	1	0	0	40	40	30	10	0	0	0	40.0099	36.1465	
19	Sri Wahyuningih (RSP)	P	25	54	150	24	18,28 B SA, 48 II B Mesio	3	0	1	0	3	0	3	21	25	30	11	43.8033	39.4802	
20	Herlina Saleh (RSP)	P	38	65	155	27.1	18,28 B SA, 38 II B Hori	3	0	1	0	12	6	3	2	30	45	33	37.8527	32.2287	
21	Nurul Muchlisah	P	32	61	158	24.4	18 A SA, 28 B SA, 38,48 II A hori	4	1	0	0	52	27	17	17	16	10	5	35.6584	33.4872	
22	Andi Lukman (RSP)	L	31	73	168	25.6	18,28 B SA, 38,48 II A Hori	4	0	1	0	24	5	6	2	0	0	0	144.9263	173.0988	
23	Muh.Kabir	L	20	72	157	29.2	18,28 B SA, 38 II B Hori, 48 II A Hori	4	1	0	0	38	4	0	0	10	2	31	43.6150	43.4871	
24	Muh.Dwi Angga	L	21	69	165	25.3	18 B SA, 28 B SA, 38 II B Mesio, 48 II A Hori	4	1	0	0	13	30	35	13	13	5	1	40.0680	37.4200	
25	Baiq Kasaluna	P	19	48	145	22.8	18 B SA, 28 C SA, 38 II B Verti, 48 II B mesio	4	1	0	0	0	0	0	0	0	0	0	48.3596	42.5993	
26	Turibius Wahyu	L	21	70	168	24.8	18,28 B SA, 38 II A Verti, 48 II B Mesio	4	1	0	0	0	52	66	24	22	9	0	0	35.5078	30.9486
27	Muhammad Idil	L	27	73	165	26.8	18,28 B SA, 38 II A Hori, 48 II A Hori	4	1	0	0	40	30	23	35	40	10	6	34.8629	34.7634	
28	Nurul Riska	P	27	47	153	20.1	18 A SA, 28 B SA, 38,48 II A Hori	4	0	1	0	50	61	71	82	90	70	42	44.5316	44.1861	
29	Sufyan Dari	L	21	88	173	23.4	18,28 B SA, 38 II B Mesio, 48 III C Hori	4	0	1	0	0	0	0	0	0	0	0	45.5896	42.9805	
30	Adi Prawira (RSP)	L	22	70	168	24.8	18 C SA, 28 B SA, 38,48 II B Hori	4	0	1	0	61	29	18	11	0	0	0	207.5073	144.2443	
31	Azizah Az Zahra	P	23	53	153	22.3	18 B SA, 28 B SA, 38 II B Mesio, 48 II B Mesio	4	0	1	0	80	60	40	30	10	5	0	43.5018	49.5906	
32	Rini Karnita	P	27	44	154	18.6	18,28 B SA, 38,48 II A Hori	4	0	1	0	30	22	15	2	0	0	0	58.8828	59.1419	
33	May Sara	P	26	53	154	22.3	18,28 B SA, 38 II A Verti, 48 II A Hori	4	0	1	0	20	10	3	0	0	0	0	41.8311	41.2617	
34	Misel Julianita (RSP)	P	26	70	170	24.2	28 B SA, 38,48 II A Hori	3	0	1	0	50	38	30	30	6	3	0	52.6048	49.1395	
35	Afifah Ridha Himairah (RSP)	P	20	48	158	19.2	18 B SA, 28 B SA, 38,48 II A Verti	4	0	1	0	50	30	20	10	0	0	0	83.2485	84.3217	
36	Muh. Rizki Ramadhan (RSF)	L	19	59	170	20.4	18,28 B SA, 38 II A Disto, 48 II A Verti	4	0	1	0	0	0	0	0	0	0	0	49.3793	49.9822	
37	Yohanis Dora Ra'da	L	20	45	156	18.5	18 B SA, 28 B SA, 38 II A Hori, 48 II B Mesio	4	0	1	0	0	22	30	9	0	0	0	0	57.0471	50.4500
38	Nur Alfiyah Dwiyanti	P	22	60	157	24.3	18 B SA, 28 B SA, 38 II B Hori, 48 II A Hori	4	0	1	0	88	76	60	52	32	15	0	53.2078	53.4755	

Lampiran 8. Hasil Analisis Data

Analisis karakteristik sampel

			Analgetik		Jumlah	Nilai p
			IBF + PCT	PCT		
JK	Laki-laki	n	12	7	19	0,194
		%	63,2%	36,8%	50,0%	
	Perempuan	n	7	12	19	
		%	36,8%	63,2%	50,0%	
Kat.IMT	Underweight	n	1	0	1	0,534
		%	5,3%	0,0%	2,6%	
	Normal	n	13	15	28	
		%	68,4%	78,9%	73,7%	
	Overweight	n	5	4	9	
		%	26,3%	21,1%	23,7%	
	Jumlah	n	19	19	38	
		%	100,0%	100,0%	100,0%	

Analisis distribusi sampel

Analgetik	IBF + PCT					PCT					Jumlah					Nilai p
	Mean	SD	Median	Minimum	Maximum	Mean	SD	Median	Minimum	Maximum	Mean	SD	Median	Minimum	Maximum	
Usia	22,16	3,64	22,00	18,00	32,00	25,21	6,19	23,00	19,00	41,00	23,68	5,24	22,50	18,00	41,00	0,113**
IMT	23,32	3,37	23,20	17,80	29,30	22,98	3,03	22,90	18,50	29,40	23,15	3,17	23,05	17,80	29,40	0,752*
Jmlh.Gigi	3,68	0,48	4,00	3,00	4,00	3,79	0,42	4,00	3,00	4,00	3,74	0,45	4,00	3,00	4,00	0,467**

* Uji t Independen

** Uji Mann Whitney

Analisis Perbandingan skor nyeri (VAS) Pada Pengukuran Antar Waktu Pada Masing-Masing kelompok

Analgetik	IBF + PCT					Nilai p	PCT					Nilai p
	Mean	SD	Median	Minimum	Maximum		Mean	SD	Median	Minimum	Maximum	
VAS.0hr	0,00	0,00	0,00	0,00	0,00	0,000	0,00	0,00	0,00	0,00	0,00	0,000
VAS.2hr	22,16	24,15	13,00	0,00	70,00		32,21	28,31	24,00	0,00	88,00	
VAS.8hr	19,63	22,59	6,00	0,00	65,00		22,79	22,12	19,00	0,00	76,00	
VAS.16hr	16,95	20,96	7,00	0,00	66,00		17,11	20,67	8,00	0,00	71,00	
VAS.24hr	11,26	13,94	5,00	0,00	43,00		15,00	21,31	6,00	0,00	82,00	

* Uji Friedman

Analisis Perbandingan Skor Nyeri (VAS) antar Kelompok pada pemeriksaan Pra Operasi, 2 Jam, 8 jam, 24 Jam Pasca Operasi

Analgetik	IBF + PCT					Nilai p	PCT					Nilai p
	Mean	SD	Median	Minimum	Maximum		Mean	SD	Median	Minimum	Maximum	
VAS.0hr	0,00	0,00	0,00	0,00	0,00	0,001	0,00	0,00	0,00	0,00	0,00	0,000
VAS.2hr	22,16	24,15	13,00	0,00	70,00		32,21	28,31	24,00	0,00	88,00	
VAS.0hr	0,00	0,00	0,00	0,00	0,00	0,001	0,00	0,00	0,00	0,00	0,00	0,000
VAS.8hr	19,63	22,59	6,00	0,00	65,00		22,79	22,12	19,00	0,00	76,00	
VAS.0hr	0,00	0,00	0,00	0,00	0,00	0,002	0,00	0,00	0,00	0,00	0,00	0,000
VAS.16hr	16,95	20,96	7,00	0,00	66,00		17,11	20,67	8,00	0,00	71,00	
VAS.0hr	0,00	0,00	0,00	0,00	0,00	0,002	0,00	0,00	0,00	0,00	0,00	0,001
VAS.24hr	11,26	13,94	5,00	0,00	43,00		15,00	21,31	6,00	0,00	82,00	
VAS.2hr	22,16	24,15	13,00	0,00	70,00	0,182	32,21	28,31	24,00	0,00	88,00	0,033
VAS.8hr	19,63	22,59	6,00	0,00	65,00		22,79	22,12	19,00	0,00	76,00	
VAS.2hr	22,16	24,15	13,00	0,00	70,00	0,146	32,21	28,31	24,00	0,00	88,00	0,014
VAS.16hr	16,95	20,96	7,00	0,00	66,00		17,11	20,67	8,00	0,00	71,00	
VAS.2hr	22,16	24,15	13,00	0,00	70,00	0,010	32,21	28,31	24,00	0,00	88,00	0,011
VAS.24hr	11,26	13,94	5,00	0,00	43,00		15,00	21,31	6,00	0,00	82,00	
VAS.8hr	19,63	22,59	6,00	0,00	65,00	0,247	22,79	22,12	19,00	0,00	76,00	0,023
VAS.16hr	16,95	20,96	7,00	0,00	66,00		17,11	20,67	8,00	0,00	71,00	
VAS.8hr	19,63	22,59	6,00	0,00	65,00	0,008	22,79	22,12	19,00	0,00	76,00	0,058
VAS.24hr	11,26	13,94	5,00	0,00	43,00		15,00	21,31	6,00	0,00	82,00	
VAS.16hr	16,95	20,96	7,00	0,00	66,00	0,066	17,11	20,67	8,00	0,00	71,00	0,271
VAS.24hr	11,26	13,94	5,00	0,00	43,00		15,00	21,31	6,00	0,00	82,00	


* Uji Wilcoxon

Analisis Perbandingan skor VAS dan nilai IL-6 antara kedua kelompok


Analgetik	IBF + PCT					PCT					Nilai p
	Mean	SD	Median	Minimum	Maximum	Mean	SD	Median	Minimum	Maximum	
VAS.2hr	22,16	24,15	13,00	0,00	70,00	32,21	28,31	24,00	0,00	88,00	0,239
VAS.8hr	19,63	22,59	6,00	0,00	65,00	22,79	22,12	19,00	0,00	76,00	0,418
VAS.16hr	16,95	20,96	7,00	0,00	66,00	17,11	20,67	8,00	0,00	71,00	0,627
VAS.24hr	11,26	13,94	5,00	0,00	43,00	15,00	21,31	6,00	0,00	82,00	0,626
POD.3	10,00	13,33	5,00	0,00	43,00	12,32	21,61	4,00	0,00	90,00	0,868
POD.5	4,63	6,52	1,00	0,00	25,00	10,95	19,79	0,00	0,00	70,00	0,963
POD.7	2,79	7,24	0,00	0,00	31,00	4,63	11,95	0,00	0,00	42,00	0,813
Pre.IL6	40,71	8,45	39,05	30,61	71,21	63,91	43,04	49,38	30,05	207,51	0,001
Post.IL6	38,11	5,41	37,42	29,69	53,57	59,01	37,58	49,14	30,76	173,10	0,003
Delta.IL6	-2,60	4,64	-1,75	-17,64	4,42	-4,89	16,76	-2,61	-63,26	28,17	0,827

* Uji Mann Whitney

Lampiran 9. Dokumentasi Kegiatan Penelitian



Pengambilan sampel darah untuk pemeriksaan IL-6



Pemeriksaan IL-6 di laboratorium penelitian RSP Unhas

Lampiran 10. Riwayat Hidup Penulis

Data Pribadi

Nama Lengkap : drg. Nilawati
Jenis kelamin ; Perempuan
Tempat, tanggal lahir : Pakkasalo, 23 Januari 1989
Agama : Islam
Status : Belum menikah
Alamat : BTN Gelora Baddoka Indah Blok A3 no.17
No. Hp : 082250701627
Email : Nilawatisakka@gmail.com



Latar Belakang Pendidikan

2019-sekarang : Program Pendidikan Dokter Gigi Spesialis Bedah
Mulut dan Maksilofasial, Fakultas Kedokteran Gigi,
Universitas Hasanuddin
2007-2012 : Fakultas Kedokteran Gigi Universitas Hasanuddin
2004-2006 : SMAN 2 Makassar
2001-2003 : SLTP 1 Sibulue
1995-2000 : SDN 226 Pakkasalo

Pengalaman Kerja

2013- 2014 : Puskesmas Sanur
2015-2019 : Puskesmas Sei Menggaris